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Genetics of Skin Cancer
This month's issue contains several reports on genetic factors
associated with various skin diseases, including melanoma and
nonmelanoma skin cancer. Melanocortin-1 (MC1R) gene variants
have been repeatedly associated with an increased risk for the
development of cutaneous melanoma, with phenotypical features
such as fair skin and red hair that carry a higher risk for both
melanoma and nonmelanoma skin cancer, but also with sun
sensitivity in many individuals without red hair. The MC1R is
located on chromosome 16q24.3 and has a high af®nity for a-
melanocyte-stimulating hormone (a-MSH). In consequence,
genetic variants of MC1R lead to changes in ligand binding, or
loss of function. This is best exempli®ed by the change from
production of the predominantly photoprotective eumelanin to
pheomelanin found in individuals with increased cancer risk.
Numerous more frequently occurring MC1R gene variants
predispose to cutaneous melanoma. The Asp84Glu allele, which
has also been investigated by others, appears to be associated with
the highest risk in the cohort of Dutch patients investigated by
Cornelis Kennedy from Jan Nico Bouwes Bavinck's group (p.
294). The power of this study lies in the large number of individuals
studied, in the most homogenous patient group, and in the large
number of MC1R gene variants investigated. Moreover, the
analyzes performed by Kennedy and coworkers showed that not all
MC1R variant alleles that were associated with melanoma, were
also associated with fair skin and/or red hair. This ®nding illustrates
that pigmentation characteristics and melanoma are independent
outcomes of the presence of MC1R gene variants. Still, further
carefully planned studies are required to strengthen the association
of particular MC1R gene variants with an increased risk of
developing melanoma, and to elucidate the mechanism(s) by which
MC1R variants modulate pigment metabolism and the effects of a-
MSH not only on proliferation and differentiation of keratinocytes
and melanocytes but also on the immune defense against genetically
changed melanocytes.
Improved access to organ transplantation and highly ef®cient
immunosuppressive treatment has resulted in a progressively
increasing incidence of nonmelanoma skin cancer (NMSC). These
transplant-associated tumors occur at a younger age, are more
numerous, grow rapidly, and metastasize earlier than in nontransplant
patients. Therefore, it is highly important to identify individuals at
greatest risk as early as possible to develop more effective strategies for
prevention and surveillance. The group of immunsuppressed patients
is not homogeneous, however, with regard to time of occurrence and
behavior of the skin tumors. Glutathione S-Transferases (GST) are
critically involved in mediating protection against oxidative stress,
and genotypic differences have already been associated with altered
risks for the development of NMSC in nontransplant patients. Helen
M. Ramsay et al (p. 251) have therefore investigated the association
between polymorphisms in GST and NMSC in renal transplant
recipients. In this study GSTM1 null was associated with increased
SCC, and was even stronger in patients with higher ultraviolet
exposure and in smokers, indicating that these factors act synergistic
with respect to shorter intervals from transplantation to development
of the ®rst tumor. Homozygosity for another allele, GSTp1*Ile, is
associated with larger numbers of SCC, particularly in individuals
with lower UV exposure and cigarette smoking. It will be highly
important in the near future to extend these studies to further patient
cohorts, to increase the numbers of individuals tested for these genetic
polymorphisms, and to con®rm the synergy with other risk factors
mediating oxidative damage in the skin and predisposing to the
development of skin tumors. And it will be critical to extend these
®ndings to the identi®cation of the transplant patients at highest risk to
develop NMSC, not only to keep the costs for extensive surgery
and chemotherapy as low as possible, but even more importantly
to improve the quality of life for those patients who are already
impairedby thedangerof organ rejection and the constant demand for
highly immunosuppressive drugs with all socioeconomical conse-
quences.
More on Neuropeptides in the Skin
Proopiomelanocortin (POMC) peptides have gained much atten-
tion in recent years because of their pluripotent biologic effects
including immunomodulating properties. a-melanocyte stimulat-
ing hormone (a-MSH) is one of the most interesting members of
this peptide family, not only because of its role in pigmentation but
also because of its immunoregulatory effects relevant for cutaneous
immune responses and in¯ammation. To gain bioactivity enzy-
matic cleavage of large precursor prohormones by two prohormone
convertases, PC1 and PC2, is needed. PC1 and PC2 belong to an
evolutionary conserved family of serine proteinases. Whereas PC1
activity is needed for ACTH and b-lipotropin formation, PC2
catalyzes the formation of a-MSH, b-endorphin (b-ED), and
corticotrophin-like intermediate lobe peptide, and its activity is
partly regulated by a chaperone-like binding protein 7B2. In this
issue Meinhard Schiller et al (p. 227) from MuÈnster present ample
evidence for expression of these enzymes by human dermal
®broblasts in vitro and in situ. In addition, the authors localize these
two prohormone convertases in the trans-Golgi network and in
vesicular structures in the peripheral cytoplasm. Moreover, the
authors describe PC1 and PC2-cytoplasmic reactivity in keratino-
cytes, in dendritic epidermal cells such as Langerhans cells and
melanocytes, in ®broblasts, and in dermal microvascular endothelial
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cells. In their in vitro system the authors provide evidence for the
functional activity of PCs by measuring upregulation of a-MSH,
ACTH, and b-ED in response to interleukin-1 (IL-1), UVB, and
PMA; however, compared with ACTH and b-ED, a-MSH
appears to be secreted only in minute amounts, and only in
response to IL-1. There is still no clear-cut evidence for a-MSH,
ACTH, and b-ED expression by ®broblasts in situ; however, based
on their in vitro data the authors may well speculate on the
relevance of PC- and a-MSH production by human dermal
®broblasts on ®broblast functions such as collagen degradation,
reduced collagen I and II deposition, and mitigated TGF-b-
induced ®brosis. Thus, in addition to immunoregulatory functions,
a-MSH may indeed act as an important autocrine or paracrine
modulator of distinct ®broblast functions. Fibroblasts may therefore
play a more important role in skin physiology or pathophysiology
than previously thought.
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